Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.49 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 4/20 | 0.54 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL5659804 | 1.00 | PARP1 (0.54) | PARP1PARP2HTR1AHTR2ATMEM97 | |
| Fumaric Acid SCHEMBL5658705 | 0.89 | TMEM97 (0.56) | PARP1HTR1AHTR2ATMEM97ACHE | |
| Fumaric Acid SCHEMBL5658700 | 0.89 | TMEM97 (0.56) | PARP1HTR1AHTR2ATMEM97ACHE | |
| Fumaric Acid SCHEMBL5660364 | 0.89 | HTR1A (0.53) | HTR1AHTR2ATMEM97ACHESIGMAR1 | |
| Fumaric Acid SCHEMBL5660370 | 0.89 | HTR1A (0.53) | HTR1AHTR2ATMEM97ACHESIGMAR1 | |
| Fumaric Acid SCHEMBL5658504 | 0.86 | HTR1A (0.50) | PARP1PARP2HTR1AHTR2ATMEM97 | |
| Fumaric Acid SCHEMBL5658505 | 0.86 | HTR1A (0.50) | PARP1PARP2HTR1AHTR2ATMEM97 | |
| Fumaric Acid SCHEMBL5249516 | 0.85 | HTR7 (0.47) | PARP1PARP2HTR1AHTR2ATMEM97 | |
| Fumaric Acid SCHEMBL5249513 | 0.85 | HTR7 (0.47) | PARP1PARP2HTR1AHTR2ATMEM97 | |
| Fumaric Acid SCHEMBL5247982 | 0.84 | HTR1A (0.64) | PARP1PARP2HTR1AHTR2ATMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166617-B2 | Cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-01-23 | — | — | US | disclosed |
| US-20030212094-A1 | Novel cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1260512-A1 | NOVEL CYCLIC AMIDE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2002-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212094-A1 | Novel cyclic amide derivatives | SIGMAR1, OPRM1, OPRD1 | HTR2A 153/4885DRD2 402/4885PARP1 4235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.